Compounded Semaglutide: Cost, Safety & How to Source (2026)

What Is Compounded Semaglutide?

Compounded semaglutide is the GLP-1 receptor agonist peptide (the same active ingredient in Ozempic and Wegovy) prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's typically supplied as lyophilized (freeze-dried) powder in vials that you reconstitute with bacteriostatic water before injection, or as a pre-mixed injectable solution.

Compounding pharmacies have been producing semaglutide since supply shortages began in 2022. Under federal law, pharmacies can compound drugs that are on the FDA's drug shortage list or when a patient has a specific medical need that can't be met by a commercially available product. This created a legal pathway for millions of people to access semaglutide at a fraction of the brand-name cost.

The compounded semaglutide market grew quickly. Chronic shortages of Ozempic and Wegovy, combined with brand-name prices above $1,000/month without insurance, pushed millions of people toward compounding pharmacies. Telehealth platforms, weight loss clinics, and direct-to-consumer services all entered the space, making compounded semaglutide one of the most widely used compounded medications in history.

Compounded vs Brand-Name Semaglutide: Key Differences

The most important distinction is quality oversight. Brand-name Ozempic and Wegovy undergo rigorous FDA review for safety, efficacy, and manufacturing quality. Compounded versions do not. This doesn't automatically mean compounded products are unsafe (many compounding pharmacies maintain high standards), but the regulatory framework is fundamentally different.

Why People Choose Compounded Semaglutide

Cost

This is the primary driver. Wegovy costs approximately $1,350–$1,865 per month without insurance. Ozempic runs $900–$1,000. Compounded semaglutide from a telehealth platform or compounding pharmacy typically costs $99–$500 per month. For many people, the math is straightforward: brand-name GLP-1s are simply unaffordable without robust insurance coverage, and many plans don't cover weight management indications.

Availability

Chronic shortages of Ozempic and Wegovy plagued the market from 2022 through early 2025. Even patients with prescriptions and insurance coverage couldn't reliably fill them. Compounding pharmacies filled this gap, providing consistent supply when Novo Nordisk couldn't meet demand.

Custom Dosing Flexibility

With compounded semaglutide, you draw your dose with an insulin syringe from a multi-dose vial. This allows precise micro-adjustments that aren't possible with a pre-filled pen. If you want to dose at 0.3mg, 0.75mg, or any non-standard increment, compounded vials make that straightforward. This flexibility is particularly useful for microdosing protocols or custom titration schedules that deviate from the standard escalation.

Combination Formulations

Many compounding pharmacies offer semaglutide combined with cyanocobalamin (vitamin B12), L-carnitine, or other ingredients. The semaglutide/B12 combination became especially common after the FDA removed semaglutide from the shortage list, since it's not an "essentially a copy" of a commercially available product, it may fall outside certain compounding restrictions.

FDA Regulatory Status: 503A vs 503B Pharmacies

If you're sourcing compounded semaglutide, you need to understand the regulatory framework. The legal framework centers on two sections of the Federal Food, Drug, and Cosmetic Act.

Section 503A Pharmacies

• What they are: Traditional state-licensed compounding pharmacies
• How they operate: Compound per individual patient prescription
• Oversight: Primarily state pharmacy boards
• Scale: Smaller batches, patient-specific
• Semaglutide status: Enforcement discretion for compounding semaglutide copies ended April 22, 2025

Section 503B Outsourcing Facilities

• What they are: FDA-registered compounding facilities
• How they operate: Can compound without individual prescriptions, produce larger batches
• Oversight: FDA inspections, adverse event reporting requirements, current Good Manufacturing Practices (cGMP)
• Scale: Larger operations, can distribute to healthcare facilities
• Semaglutide status: Enforcement discretion for compounding semaglutide copies ended May 22, 2025

The regulatory situation remains fluid. Some compounders continue operating under various legal arguments (different salt forms, combination products, or state-specific exemptions). If you're currently using compounded semaglutide, the practical impact depends on your specific pharmacy and their approach to compliance.

How to Source Compounded Semaglutide Safely

If you're going to use compounded semaglutide, where you get it matters. A legitimate compounding pharmacy produces a well-characterized product. A questionable operation is a gamble.

What to Look For

• State license verification: Confirm the pharmacy is licensed in your state through your state's board of pharmacy website
• 503B registration: If they claim to be a 503B outsourcing facility, verify on the FDA's registered outsourcing facility list
• Third-party testing: Reputable pharmacies test each batch for potency, purity, sterility, and endotoxins, and can provide certificates of analysis (COAs) on request
• Prescription requirement: Any legitimate pharmacy requires a valid prescription from a licensed provider. No prescription = no legitimacy
• Proper shipping: Injectable semaglutide requires cold chain shipping. If it arrives warm or without adequate ice packs, don't use it
• Clear labeling: Labels should include the pharmacy name and address, compound name and concentration, beyond-use date, storage instructions, and lot number

Telehealth Platforms

Services like Hims, Ro, Sesame, and Henry Meds connect you with a prescriber and source from contracted compounding pharmacies. This is a valid pathway, but verify which pharmacy actually compounds your product. The telehealth company is the front end; the pharmacy is what matters for product quality.

Dosing Considerations for Compounded Semaglutide

The standard semaglutide titration protocol applies regardless of whether you're using brand-name or compounded product. The semaglutide dosing guide covers this in detail, and you can download a printable semaglutide dosage chart for quick reference. Here's the standard Wegovy escalation:

Compounded Semaglutide Concentrations

Compounded semaglutide vials come in various concentrations, commonly 2mg, 5mg, or 10mg total peptide content per vial. The concentration after reconstitution depends on how much bacteriostatic water you add. For example:

• 5mg vial + 2mL BAC water = 2.5mg/mL concentration
• 5mg vial + 1mL BAC water = 5mg/mL concentration
• 10mg vial + 2mL BAC water = 5mg/mL concentration

The higher the concentration, the smaller the injection volume, but the higher the risk of a significant dosing error from a small measurement mistake. Use the semaglutide calculator to plan your schedule and visualize how your dose translates to blood levels over time.

Reconstitution Basics

If your compounded semaglutide arrives as lyophilized powder, you'll need to reconstitute it before use. Our semaglutide reconstitution guide covers this in full detail. Here's the essential process:

1. Gather supplies: Bacteriostatic water (BAC water), alcohol swabs, insulin syringes, and your semaglutide vial
2. Clean the vial tops: Wipe both the semaglutide vial and BAC water vial with alcohol swabs
3. Draw BAC water: Using a syringe, draw your chosen volume of bacteriostatic water
4. Inject slowly: Insert the needle into the semaglutide vial and inject the BAC water slowly down the side of the vial. Don't spray directly onto the powder
5. Gently swirl: Roll the vial between your palms. Never shake; this can damage the peptide
6. Wait for full dissolution: The solution should be clear and colorless. If particles remain, continue gently swirling

Storage and Stability

Proper storage is critical for maintaining peptide integrity. Semaglutide degrades when exposed to heat, light, or repeated temperature fluctuations.

Before Reconstitution

• Lyophilized powder: Store refrigerated (2–8°C / 36–46°F). Most suppliers indicate stability of 12–24 months when stored properly
• Room temperature: Brief periods at room temperature during shipping are generally acceptable, but prolonged exposure above 25°C (77°F) degrades the peptide
• Protect from light: Keep in the original packaging or a dark container

After Reconstitution

• Refrigerate immediately: Store reconstituted vials at 2–8°C (36–46°F)
• Beyond-use date: Most compounding pharmacies assign a 28–30 day beyond-use date after reconstitution when stored refrigerated. Check your specific pharmacy's labeling
• Never freeze: Freezing reconstituted semaglutide can damage the peptide structure
• Inspect before each use: The solution should remain clear and colorless. Discard if you see cloudiness, particles, or discoloration

Safety Considerations and Red Flags

Compounded semaglutide is not inherently dangerous, but it carries risks that brand-name products don't. Here's what to watch for.

Known Safety Concerns

Dosing errors: The FDA has received multiple adverse event reports (some requiring hospitalization) from dosing mistakes with compounded semaglutide. This happens when patients miscalculate the volume to draw, or when providers prescribe incorrect concentrations. The risk is highest with high-concentration vials where small volume differences represent large dose changes.

Salt form confusion: Not all compounded "semaglutide" uses the same form of the molecule. FDA-approved semaglutide uses the base form. Some compounders use semaglutide sodium or semaglutide acetate, different salt forms that the FDA has explicitly stated "have not been shown to be safe and effective." If your product specifies a salt form, understand that it has not undergone the same testing as the base form used in clinical trials.

Sterility and purity: Compounded injectables must be prepared under sterile conditions. A 503B facility with FDA oversight and cGMP compliance is more likely to maintain consistent sterility than a smaller 503A pharmacy, though both can produce quality products when properly operated.

Adverse event tracking: Brand-name drug manufacturers are required to track and report adverse events to the FDA. 503B outsourcing facilities have reporting requirements, but 503A pharmacies generally do not. This means safety signals from 503A-compounded products may go undetected longer.

FDA Adverse Event Data

As of mid-2025, the FDA had received approximately 600 adverse event reports related to compounded semaglutide products. Reported issues included:

• Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain)
• Fainting and dehydration
• Pancreatitis
• Gallstones requiring hospitalization
• Injection site reactions (with fraudulent products)

Context matters here: many of these side effects also occur with FDA-approved semaglutide. The question is whether compounded products produce these effects at higher rates, and that data doesn't exist yet. What is clear is that dosing errors specific to compounded products (drawing wrong volumes, miscalculating concentrations) have caused preventable adverse events. For a full overview of what to expect, see our semaglutide side effects guide.

Fraudulent Products

The FDA has identified fraudulent compounded semaglutide products circulating in the US market. Some products carry labels from pharmacies that don't exist. Others use the names of real pharmacies that didn't actually compound the product. This is particularly concerning because there's no way to know what's in a fraudulent vial: it could be underdosed, overdosed, contaminated, or contain no semaglutide at all.